

Case Study Open Access

Vaccination Counselling with and without Excipient Skin Testing in Patients with Atopy and Suspected Allergic Reactions to mRNA COVID-19 Vaccines

Sana Kovazki*

Department of Internal Medicine, Division of Allergy and Clinical Immunology, Mosambique

Abstract

Background: Antipathetic responses have been reported with mRNA vaccines for COVID- 19 forestalment. Cases perceived to be at advanced threat for a response may be appertained to an allergist, although evaluation strategies { æ^Ååå ^\Åà^c,^^}\æ|\^*åec*\ÅF\ÅGÅÅ

Objective: Our end was to determine issues of COVID- 19 vaccinations in cases estimated by an allergist using åå ^\^}dæ]]![æ&@^•Ĥ

Method: We conducted a retrospective case series evaluation of 98 cases seen at the University of Michigan Allergy Clinic for enterprises regarding COVID- 19 vaccination. Of these 98 cases, 34 passed skin testing with

and tolerate vaccination without complication.

Keywords: COVID-19 acciffe; acciffe a e.g; e.h effe g c e. ba.e 80

Introduction

Se e.e ac., e.e, i.a., . . a., e. | c. , | a i., 2 (SARS-C V-2) i a. a.h ge flic c . Ha i., .ha, . .faced in December f 2019.1 Since a , , SARS- C V- 2 ha , . .ead ee. ac , .he g be, .e.f . . ing in .he c Mai c a ai 2019 (COVID-19) a ide jc. T c ba. .hi a ide jc, e e a acci ne ha e been de e ced. In he United S.a.e, he a ai ab e $\mbox{acci}_{\mbox{\scriptsize TR}}$ e i $\mbox{\scriptsize TC}$ de 2 $\mbox{\scriptsize _RNA-}$ g. $\mbox{\scriptsize \tiny T}$ ded $\mbox{\scriptsize COVID-}$ 19 acci le, he P. e. Bi NTech (BNT162b2) a ld M de la (RNA-1273) accine, a e a he aden i ec. g nded Jan, en JNJ-78436735 accine. [4] Dec i.e., he high e ec.i ene, f .he COVID-19 acci**f**e, .he fac. .ha. .hei a, f .e .. fi , edia e and be a ed .e. η e , inc ding and h a i, 6 ged ec genda, in f. he US Cente, f. Di ea e C n. and P.e eni n c n.aindica.ing COVID-19 accine in ca, e. i.h a hi . . . f a \P i . . . edia e a \P i a he ic . e. \P e . . he . . . c . e f a acciffe . acciffe e ci ieff, i i a a (e.h effe g c (c.), hich i , e. (iff RNA acciffe) . ba.e 80, hich i , e. in the Jan, en accine [5]. i ha gene a ed igni can ca e and ide c $\|ce\|$ ab . . . he afe. f . he e acci $\|e\|$, i a . ic a i $\|$.h, e, i,hahi, ... fa. (. [] e, ... i [di id. a i,ie, a,e [] ..., ee i [] g ec enda i n ega ding COVID-19 accina i n f a e gi, , b, e a a i n and ec endain a a be een c a e .
en e e e e e e e e e e e e e ingc a e i ha e n RNA COVID-19 accipali panda, e, ingca e, i had e, ee en, a. ib. ed. RNA COVID-19 accipali [6].

Methods

We c ¶d cled a lel jo ecli e caje jeliej e a ali ¶ f cajej

e ening. he Unie, i f Michigan j i e cinic f accine g. h f j i e e a ai n and f bea ance f fa he COVID-19 accina in [7]. e de and f j i e e ing a de e ined a he dice in f he ca e e eaing a e gi and c eci e deci in a ing ih c n ide ai n f i a aing i efe ence, 2- Di j i acc-g ce -3- gh e eh ene g c - 2000 (DMG-c. 2000) a a ained f Anni P a Li id (Aaba e, Aa). We ec n i ed 1 g f DMG-PEG 2000 in 10 L f e i e di en f .

*Corresponding author: Sana Kovazki, Department of Internal Medicine, Division of Allergy and Clinical Immunology, mosambique, E-mail: skova@med.umich.edu

Received: GÍÉRæ}ĚG€GHĖÁTæ}`*&¦i]dÞ[Ėlà {ĒGHĒÌJÎÌJLÆditor assigned:kGÌĒRæ}ĒG€GHĖÚ!^ÛÔÁÞ[Ēlà {ĒGHĒÌJÎÌJLÆeviewed:kFFĒØ^àĒG€GHĖkÛOÂÞ[Ēlà {ĒGHĒÌJÎÌJLÆeviewed:kFFĒØ^àĒG€GHĖkÛÔÅÞ[Ēlà {ĒGHĒÌJÎÌJLÆeviewed:kFFĒØ^àĒG€GHĖkÛDĀÞĒ BĀBĀĀĒG€GHĖ Tæ}`*&¦i]dÞ[Ėlà {ĒGHĒÌJÎÌJÇÜDLÁ Published:kGìĒØ^àĒG€GHĖKÖUUMF€ĖIFÏGBGHÌFĒÌÏGĪĒF€€€G€Ï

Citation: Kovazki S ÇG∈GHDÁ Xæ&&}æi[}ÅÔ[`}•^||i}**\ io@Áæ}äÅ jio@[`ckÒ¢&i]i^}o\
Ù\i}ÁV^•ci}**hi}ÅÚœi^}c•∱ jio@ÁŒc[]^Áæ}äÅÜ`•]^c&c^åÅŒ||^!*i&ÄÜ^æ&di[]•Åc[Å {ÜÞŒÅ
COVID-19 VaccinesĚki}ckRki}'æ{kÔæ}&^!ki}c^*!ÁV@^!ÉÁF€kkG€ÏÉ

Copyright: © G€GHÄKovazki S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Results

Discussion